Skip to search formSkip to main contentSkip to account menu

labedipinedilol A

Known as: labedipinedilol-A 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

AnisolesDihydropyridines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Inhibition of voltage-gated L-type calcium channels by labedipinedilol-A involves protein kinase C in rat cerebrovascular smooth muscle cells.
2005
2005
The Vasorelaxing Action of Labedipinedilol-A Involves Endothelial Cell-Derived NO and eNOS Expression Caused by Calcium Influx
Labedipinedilol-A, a novel dihydropyridine-type calcium antagonist, has been shown to induce hypotension and vasorelaxation. The… 
2005
2005
Labedipinedilol-C: A Third-Generation Dihydropyridine-Type Calcium Channel Antagonist Displaying K+ Channel Opening, NO-Dependent and Adrenergic Antagonist Activities
Intravenous and oral labedipinedilol-C showed a dose-dependent long-lasting hypotension and a decrease of heart rate in… 
2001
2001
Third‐generation dihydropyridine‐type calcium channel blocker labedipinedilol‐B displays α/β‐adrenoceptor blocking activities
The pharmacological properties of labedipinedilol‐B {N‐[4‐[2‐hydroxy‐3‐(2‐methoxy‐1‐oxyethylaminobenzene) propoxy]‐benzyl]‐2,6… 
2000
2000
Labedipinedilol‐A: A vanilloid‐based α/β‐adrenoceptor blocker with calcium entry blocking and long‐acting antihypertensive properties
The combination of β‐adrenoceptor blockade and vasodilator action have proved highly useful in antihypertensive therapy. Studies… 
2000
2000
Labedipinedilol-A與KMUP 880708之甲型腎上腺激性受體阻斷相關蛋白激酶C活性之影響
During the past decade, various vanilloid-base b-adrenoceptor blockers have been investigated in our laboratory. Among them… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)